Madrigal NASH trials exceed expectations

Today was a much anticipated date in the search for the first medical treatment for NASH.  Madrigal Pharmaceuticals, a Pennsylvania-based Bio-Pharma company, has been running clinical trials with its NASH candidate MGL-3196, and was due to announce the preliminary results of those trials.

And the results blew away all expectations according to Bloomberg, leading to a 140% gain in the companies stock.   Continue reading “Madrigal NASH trials exceed expectations”